IPM Take
This is bigger than another positive lung-cancer trial. Pembrolizumab has helped define first-line immunotherapy for advanced NSCLC. HARMONi-2 now shows a PD-1/VEGF bispecific improving both PFS and OS against that benchmark. The next debate will be global: regulatory acceptance, generalisability beyond China, price, manufacturing and whether bispecific immunotherapy can realistically displace an entrenched standard.
Executive Summary
At the IASLC 2026 World Conference on Lung Cancer, the prespecified interim overall-survival analysis of the Phase III HARMONi-2 trial showed median overall survival of 30.8 months with ivonescimab versus 22.6 months with pembrolizumab in previously untreated PD-L1-positive advanced NSCLC, with a hazard ratio of 0.73. The trial enrolled 398 patients in China. HARMONi-2 had already demonstrated median progression-free survival of 11.1 versus 5.8 months. The new OS benefit was statistically significant, while treatment-related serious adverse events were somewhat more frequent with ivonescimab.
Why it matters
- Patients / advocates: A chemotherapy-free first-line option delivering longer survival could be meaningful, but global availability is unresolved.
- Clinicians: The result challenges pembrolizumab monotherapy in PD-L1-positive advanced NSCLC.
- Regulators: Evidence generated entirely in China will test how agencies judge generalisability across populations.
- Payers / HTA bodies: A new bispecific standard would trigger major comparative-value and affordability questions.
Pembrolizumab is not an easy comparator to beat. That is exactly why this result matters.
For years, PD-1 blockade has sat at the centre of first-line treatment for PD-L1-positive advanced non-small cell lung cancer. HARMONi-2 now puts a serious challenger across the table. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, first beat pembrolizumab on progression-free survival. It has now done the harder thing: show a statistically significant overall-survival advantage.
Median survival was 30.8 months versus 22.6 months. That is not a marginal numerical wobble. It changes the conversation.
The mechanism is part of the attraction. Instead of blocking only an immune checkpoint, ivonescimab is designed to combine immune activation with VEGF inhibition in one molecule. The proposition is elegant: target two biological drivers without automatically reaching for chemotherapy.
But the politics now start.
The trial was conducted across centres in China. That does not invalidate the result. It does mean regulators, guideline bodies and health systems outside China will need to examine whether the magnitude of benefit reproduces across populations, treatment settings and real-world practice.
Cost will matter too. New oncology standards do not replace old ones in a vacuum. They enter procurement systems, reimbursement negotiations and hospitals already carrying enormous immunotherapy expenditure.
And pembrolizumab is deeply embedded. Beating it scientifically is one thing. Displacing it globally is another.
HARMONi-2 has done enough to force the question. The burden now shifts from the trial to the system.
